Evidence map›Paper›PMID 24430784›Full record

ArticleCNS drugs2014

Cranioselectivity of sumatriptan revisited: pronounced contractions to sumatriptan in small human isolated coronary artery.

Kayi Y Chan, Sieneke Labruijere, Martha B Ramírez Rosas, René de Vries, Ingrid M Garrelds, Alexander H J Danser, Carlos M Villalón, Antoon van den Bogaerdt, Clemens Dirven, Antoinette MaassenVanDenBrink

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Kayi Y ChanDepartment of Internal Medicine, Division of Pharmacology, Erasmus Medical Centre, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Sieneke Labruijere
Martha B Ramírez Rosas
René de Vries
Ingrid M Garrelds
Alexander H J Danser
Carlos M Villalón
Antoon van den Bogaerdt
Clemens Dirven
Antoinette MaassenVanDenBrink
Erasmus University Rotterdam · NLCenter for Research and Advanced Studies of the National Polytechnic Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInitial concerns about the coronary side-effect potential of the anti-migraine drug sumatriptan and second-generation triptans initiated cranioselectivity studies using proximal human coronary arteries. However, myocardial ischaemia may originate from both large and small human coronary arteries.

methodsWe investigated the contractions to sumatriptan in proximal (internal diameter 2-3 mm), distal (internal diameter 1,000-1,500 μm) and small (internal diameter 500-1,000 μm) human epicardial coronary arteries and compared these with contractions in the human middle meningeal artery. Concentration response curves to sumatriptan in human coronary arteries were constructed in the absence or presence of the 5-hydroxytryptamine1B (5-HT1B) receptor antagonist SB224289 and the 5-HT1D receptor antagonist BRL15572. The effect of sumatriptan on increased cyclic adenosine monophosphate (cAMP) levels induced by forskolin in proximal and distal coronary artery segments was investigated using a biochemical assay. Western blotting was used to analyse the 5-HT1B receptor density in the human arteries.

resultsContractions in the proximal human coronary artery were significantly smaller than those in the human meningeal artery, as we showed previously. In contrast, contractions to sumatriptan in distal and small human coronary arteries were not different from those in the human meningeal artery. The 5-HT1B receptor antagonist SB224289, but not the 5-HT1D receptor antagonist BRL15572, inhibited the contraction induced by sumatriptan in the coronary arteries. Moreover, in distal, but not in proximal, coronary arteries, sumatriptan inhibited the increase in cAMP levels induced by forskolin. Contrary to our expectations, the 5-HT1B receptor expression was more pronounced in the proximal human coronary artery than in the distal and small human coronary artery.

conclusionsBased on functional experiments in distal and small human coronary arteries, contractions to sumatriptan are not as cranioselective as previously assumed. However, the vast clinical experience with sumatriptan and other triptans has proven that these drugs are cardiovascularly safe when contraindications are taken into account.

Indexed as

AdolescentAdultAgedBiphenyl CompoundsChildColforsinCoronary VesselsCyclic AMPDose-Response Relationship, DrugFemaleHumansMaleMeningeal ArteriesMiddle AgedMuscle ContractionPiperazinesBiphenyl CompoundsBRL 15572ColforsinCyclic AMPPiperazinesPiperidonesSB 22489GSerotonin 5-HT1 Receptor AgonistsSerotonin 5-HT1 Receptor AntagonistsSpiro CompoundsSumatriptanVasoconstrictor AgentsVasodilator Agents

Identifiers

PMID24430784
OpenAlexW2070541909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.